Therapeutic Regulation of Macrophage Polarization for Diabetic Kidney Disease by Targeted Metabolic Reprogramming

Abstract

Diabetic kidney disease (DKD) is one of the most common microvascular complications of diabetes. It can be identified by thickening of the glomerular basement membrane, reduced glomerular filtration rate, and persistent proteinuria. Macrophages play a key role in the pathogenesis of DKD, and their phenotype (M1 and M2) is finely regulated by metabolic reprogramming. M1 macrophages exacerbate inflammatory damage and fibrosis in renal tissue by secreting pro-inflammatory mediators and reactive oxygen species (ROS). M2 macrophages (further subdivided into M2a, M2b, M2c and M2d subtypes) primarily exert anti-inflammatory and tissue-repairing effects. Of these, the M2a and M2c subtypes are particularly crucial for anti-inflammatory repair. This study aimed to systematically review the mechanisms by which glucose, lipid, amino acid, and mitochondrial function-related metabolism influence macrophage polarization. It further explored therapeutic strategies to mitigate renal inflammation and fibrosis by regulating macrophage polarization through targeted metabolic pathways, including inhibiting glycolysis, promoting fatty acid oxidation, modulating amino acid metabolism, and enhancing mitochondrial biogenesis and oxidative phosphorylation (OXPHOS). Several natural compounds and synthetic drugs exhibit the potential to induce M2 polarization and suppress M1 polarization through metabolic reprogramming, thereby offering new directions for optimizing therapeutic strategies for DKD.

Keywords

Metabolic reprogramming / Macrophage polarization / Macrophage phenotype / Diabetic kidney disease / Renal fibrosis / Mitochondrial function / Diabetes complications

References

[1] Tuttle KR, Agarwal R, Alpers CE, et al. . Molecular mechanisms and therapeutic targets for diabetic kidney disease. Kidney Int., 2022, 102(2): 248-260

[2] Młynarska E, Buławska D, Czarnik W, et al. . Novel insights into diabetic kidney disease. Int J Mol Sci., 2024, 25(18): 10222

[3] Wang M, Pang Y, Guo Y, et al. . Metabolic reprogramming: a novel therapeutic target in diabetic kidney disease. Front Pharmacol., 2022, 13 970601

[4] Wen Y, Yan HR, Wang B, et al. . Macrophage heterogeneity in kidney injury and fibrosis. Front Immunol., 2021, 12 681748

[5] Youssef N, Noureldein MH, Riachi ME, et al. . Macrophage polarization and signaling in diabetic kidney disease: a catalyst for disease progression. Am J Physiol Renal Physiol., 2024, 326(3): F301-F312

[6] Russo S, Kwiatkowski M, Govorukhina N, et al. . Meta-inflammation and metabolic reprogramming of macrophages in diabetes and obesity: the importance of metabolites. Front Immunol., 2021, 12 746151

[7] Ito S, Nakashima H, Ishikiriyama T, et al. . Effects of a CCR2 antagonist on macrophages and Toll-like receptor 9 expression in a mouse model of diabetic nephropathy. Am J Physiol Renal Physiol., 2021, 321(6): F757-F770

[8] Guan F, Wang R, Yi Z, et al. . Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets. Signal Transduct Target Ther., 2025, 10(1): 93

[9] Zhang YL, Tang TT, Wang B, et al. . Identification of a novel ECM remodeling macrophage subset in AKI to CKD transition by integrative spatial and single-cell analysis. Adv Sci (Weinh)., 2024, 11(38): e2309752

[10] Kloc M, Halasa M, Ghobrial RM. Macrophage niche imprinting as a determinant of macrophage identity and function. Cell Immunol., 2024, 399–400 104825

[11] Li HD, You YK, Shao BY, et al. . Roles and crosstalks of macrophages in diabetic nephropathy. Front Immunol., 2022, 13: 1015142

[12] Lin DW, Yang TM, Ho C, et al. . Targeting macrophages: therapeutic approaches in diabetic kidney disease. Int J Mol Sci., 2024, 25(8): 4350

[13] Zhao L, Tang S, Chen F, et al. . Regulation of macrophage polarization by targeted metabolic reprogramming for the treatment of lupus nephritis. Mol Med., 2024, 30(1): 96

[14] Luo L, Wang S, Hu Y, et al. . Precisely regulating M2 subtype macrophages for renal fibrosis resolution. ACS Nano., 2023, 17(22): 22508-22526

[15] Chandel NS. Glycolysis. Cold Spring Harb Perspect Biol., 2021, 13(5): a040535

[16] Jia Y, Chen J, Zheng Z, et al. . Tubular epithelial cell-derived extracellular vesicles induce macrophage glycolysis by stabilizing HIF-1α in diabetic kidney disease. Mol Med., 2022, 28(1): 95

[17] Yang Y, Zhan X, Zhang C, et al. . USP25-PKM2-glycolysis axis contributes to ischemia reperfusion-induced acute kidney injury by promoting M1-like macrophage polarization and proinflammatory response. Clin Immunol., 2023, 251 109279

[18] Diao RX, Lv WY, Wang YC, et al. . Aquaporin-1 facilitates macrophage M1 polarization by enhancing glycolysis through the activation of HIF1α in lipopolysaccharide-induced acute kidney injury. Inflammation., 2025, 48(4): 1775-1790

[19] Xiang T, Wang X, Huang S, et al. . Inhibition of PKM2 by shikonin impedes TGF-β1 expression by repressing histone lactylation to alleviate renal fibrosis. Phytomedicine., 2025, 136 156324

[20] TeSlaa T, Ralser M, Fan J, et al. . The pentose phosphate pathway in health and disease. Nat Metab., 2023, 5(8): 1275-1289

[21] Dionísio F, Tomas L, Schulz C. Glycolytic side pathways regulating macrophage inflammatory phenotypes and functions. Am J Physiol Cell Physiol., 2023, 324(2): C558-C564

[22] Makassy D, Williams K, Karwi QG. The evolving role of macrophage metabolic reprogramming in obesity. Can J Cardiol., 2025, 41(9): 1736-1752

[23] Fang Z, Liu R, Xie J, et al. . Molecular mechanism of renal lipid accumulation in diabetic kidney disease. J Cell Mol Med., 2024, 28(11): e18364

[24] Wei Y, Yang H, Zhou L, et al. . Targeting lipid metabolic reprogramming to alleviate diabetic kidney disease: molecular insights and therapeutic strategies. Front Immunol., 2025, 16: 1549484

[25] Rong J, Zhang Z, Peng X, et al. . Mechanisms of hepatic and renal injury in lipid metabolism disorders in metabolic syndrome. Int J Biol Sci., 2024, 20(12): 4783-4798

[26] Wang Y, Liu T, Wu Y, et al. . Lipid homeostasis in diabetic kidney disease. Int J Biol Sci., 2024, 20(10): 3710-3724

[27] Arimura N, Watanabe H, Kato H, et al. . Advanced oxidation protein products contribute to chronic-kidney-disease-induced adipose inflammation through macrophage activation. Toxins., 2023, 15(3): 179

[28] Gnemmi V, Li Q, Ma Q, et al. . Asymptomatic hyperuricemia promotes recovery from ischemic organ injury by modulating the phenotype of macrophages. Cells., 2022, 11(4): 626

[29] Wallner S, Orsó E, Grandl M, et al. . Phosphatidylcholine and phosphatidylethanolamine plasmalogens in lipid loaded human macrophages. PLoS One., 2018, 13(10): e0205706

[30] Olona A, Hateley C, Muralidharan S, et al. . Sphingolipid metabolism during Toll-like receptor 4 (TLR4)-mediated macrophage activation. Br J Pharmacol., 2021, 178(23): 4575-4587

[31] Ghosh M, Thangada S, Dasgupta O, et al. . Cell-intrinsic sphingosine kinase 2 promotes macrophage polarization and renal inflammation in response to unilateral ureteral obstruction. PLoS One., 2018, 13(3): e0194053

[32] Mitrofanova A, Burke G, Merscher S, et al. . New insights into renal lipid dysmetabolism in diabetic kidney disease. World J Diabetes., 2021, 12(5): 524-540

[33] Qi H. Desmosterol-driven atypical macrophage polarization regulates podocyte dynamics in diabetic nephropathy. Mol Biol Rep., 2024, 51(1): 213

[34] Kauerova S, Bartuskova H, Muffova B, et al. . Statins directly influence the polarization of adipose tissue macrophages: a role in chronic inflammation. Biomedicines., 2021, 9(2): 211

[35] Ryu JH, Ge M, Merscher S, et al. . APOL1 renal risk variants promote cholesterol accumulation in tissues and cultured macrophages from APOL1 transgenic mice. PLoS One., 2019, 14(4): e0211559

[36] Kieler M, Hofmann M, Schabbauer G. More than just protein building blocks: how amino acids and related metabolic pathways fuel macrophage polarization. FEBS J., 2021, 288(12): 3694-3714

[37] Li R, Li Y, Jiang K, et al. . Lighting up arginine metabolism reveals its functional diversity in physiology and pathology. Cell Metab., 2025, 37(1): 291-304.e9

[38] Zhang K, Jagannath C. Crosstalk between metabolism and epigenetics during macrophage polarization. Epigenetics Chromatin., 2025, 18(1): 16

[39] Cui P, Chen C, Cui Y, et al. . DsbA-L deletion attenuates LPS-induced acute kidney injury by modulating macrophage polarization. Eur J Immunol., 2023, 53(10): e2250071

[40] Navaneethabalakrishnan S, Goodlett BL, Smith HL, et al. . Differential changes in end organ immune cells and inflammation in salt-sensitive hypertension: effects of increasing M2 macrophages. Clin Sci (Lond)., 2024, 138(14): 921-940

[41] Zakrocka I, Załuska W. Kynurenine pathway in kidney diseases. Pharmacol Rep., 2022, 74(1): 27-39

[42] Li YX, Lu YP, Tang D, et al. . Anthocyanin improves kidney function in diabetic kidney disease by regulating amino acid metabolism. J Transl Med., 2022, 20(1): 510

[43] Sowers ML, Tang H, Singh VK, et al. . Multi-OMICs analysis reveals metabolic and epigenetic changes associated with macrophage polarization. J Biol Chem., 2022, 298(10): 102418

[44] Krupa A, Krupa MM, Pawlak K. Indoleamine 2, 3 dioxygenase 1-the potential link between the innate immunity and the ischemia-reperfusion-induced acute kidney injury?. Int J Mol Sci., 2022, 23(11): 6176

[45] Li Y, Luo Y, Hu Y, et al. . Network pharmacology and multi-omics validation of the Jianpi-Yishen formula in the treatment of chronic kidney disease. Front Immunol., 2024, 15: 1512519

[46] He L, Ding Y, Zhou X, et al. . Serine signaling governs metabolic homeostasis and health. Trends Endocrinol Metab., 2023, 34(6): 361-372

[47] Rousseau M, Denhez B, Spino C, et al. . Reduction of DUSP4 contributes to podocytes oxidative stress, insulin resistance and diabetic nephropathy. Biochem Biophys Res Commun., 2022, 624: 127-133

[48] Bouslama R, Dumont V, Lindfors S, et al. . Phosphorylation of PACSIN2 at S313 regulates podocyte architecture in coordination with N-WASP. Cells., 2023, 12(11): 1487

[49] Huang X, Yang X, Xiang L, et al. . Serine metabolism in macrophage polarization. Inflamm Res., 2024, 73(1): 83-98

[50] Shan X, Hu P, Ni L, et al. . Serine metabolism orchestrates macrophage polarization by regulating the IGF1-p38 axis. Cell Mol Immunol., 2022, 19(11): 1263-1278

[51] Chen S, Xia Y, He F, et al. . Serine supports IL-1β production in macrophages through mTOR signaling. Front Immunol., 2020, 11: 1866

[52] Li C, Gao L, Lv C, et al. . Active role of amino acid metabolism in early diagnosis and treatment of diabetic kidney disease. Front Nutr., 2023, 10: 1239838

[53] Nasri M, Adibhesami G, Mahdavifard S, et al. . Exogenous glutamine ameliorates diabetic nephropathy in a rat model of type 2 diabetes mellitus through its antioxidant and anti-inflammatory activities. Arch Physiol Biochem., 2023, 129(2): 363-372

[54] Liu L, Xu J, Zhang Z, et al. . Metabolic homeostasis of amino acids and diabetic kidney disease. Nutrients., 2022, 15(1): 184

[55] Castegna A, Menga A. Glutamine synthetase: localization dictates outcome. Genes., 2018, 9(2): 108

[56] Sharma A, Vikramdeo KS, Sudan SK, et al. . Cortisol affects macrophage polarization by inducing miR-143/145 cluster to reprogram glucose metabolism and by promoting TCA cycle anaplerosis. J Biol Chem., 2024, 300(10): 107753

[57] Xia R, Peng HF, Zhang X, et al. . Comprehensive review of amino acid transporters as therapeutic targets. Int J Biol Macromol., 2024, 260(Pt 2): 129646

[58] Kim S, Kang SW, Joo J, et al. . Characterization of ferroptosis in kidney tubular cell death under diabetic conditions. Cell Death Dis., 2021, 12(2): 160

[59] Sheng L, Luo Q, Chen L. Amino acid solute carrier transporters in inflammation and autoimmunity. Drug Metab Dispos, 2022, 50(9): DMD–AR–2021–000705

[60] Gan Z, Guo Y, Zhao M, et al. . Excitatory amino acid transporter supports inflammatory macrophage responses. Sci Bull., 2024, 69(15): 2405-2419

[61] Lunyera J, Diamantidis CJ, Bosworth HB, et al. . Urine tricarboxylic acid cycle signatures of early-stage diabetic kidney disease. Metabolomics., 2021, 18(1): 5

[62] Liu JJ, Liu S, Zheng H, et al. . Urine tricarboxylic acid cycle metabolites and risk of end-stage kidney disease in patients with type 2 diabetes. J Clin Endocrinol Metab., 2025, 110(2): e321-e329

[63] Ye L, Jiang Y, Zhang M. Crosstalk between glucose metabolism, lactate production and immune response modulation. Cytokine Growth Factor Rev., 2022, 68: 81-92

[64] Shan X, Ji Z, Wang B, et al. . Riboflavin kinase binds and activates inducible nitric oxide synthase to reprogram macrophage polarization. Redox Biol., 2024, 78 103413

[65] Shi J, Cai C. Research progress on the mechanism of itaconate regulating macrophage immunometabolism. Front Immunol., 2022, 13 937247

[66] He S, Zhao Y, Wang G, et al. . 4-Octyl itaconate attenuates glycemic deterioration by regulating macrophage polarization in mouse models of type 1 diabetes. Mol Med., 2023, 29(1): 31

[67] Zhao W, Xu D, Hong W, et al. . Grossamide attenuates inflammation by balancing macrophage polarization through metabolic reprogramming of macrophages in mice. Int Immunopharmacol., 2022, 112 109190

[68] Ito M, Gurumani MZ, Merscher S, et al. . Glucose- and non-glucose-induced mitochondrial dysfunction in diabetic kidney disease. Biomolecules., 2022, 12(3): 351

[69] Narongkiatikhun P, Choi YJ, Hampson H, et al. . Unraveling diabetic kidney disease: the roles of mitochondrial dysfunction and immunometabolism. Kidney Int Rep., 2024, 9(12): 3386-3402

[70] Li F, Xia Y, Yuan S, et al. . α-aminobutyric acid constrains macrophage-associated inflammatory diseases through metabolic reprogramming and epigenetic modification. Int J Mol Sci., 2023, 24(13): 10444

[71] Wang Y, Tang B, Long L, et al. . Improvement of obesity-associated disorders by a small-molecule drug targeting mitochondria of adipose tissue macrophages. Nat Commun., 2021, 12(1): 102

[72] Liu Y, Kors L, Butter LM, et al. . NLRX1 prevents M2 macrophage polarization and excessive renal fibrosis in chronic obstructive nephropathy. Cells., 2023, 13(1): 23

[73] Montford JR, Bauer C, Rahkola J, et al. . 15-Lipoxygenase worsens renal fibrosis, inflammation, and metabolism in a murine model of ureteral obstruction. Am J Physiol Renal Physiol., 2022, 322(1): F105-F119

[74] Pei X, Liu J, Wei Y, et al. . PINK1 affects mitochondrial oxidative phosphorylation by regulating MFN2 to alleviate diabetic kidney disease. Int Immunopharmacol., 2025, 157 114786

[75] Chen W, Zhao H, Li Y. Mitochondrial dynamics in health and disease: mechanisms and potential targets. Signal Transduct Target Ther., 2023, 8(1): 333

[76] Ahmad AA, Draves SO, Rosca M. Mitochondria in diabetic kidney disease. Cells., 2021, 10(11): 2945

[77] Mise K, Long J, Galvan DL, et al. . NDUFS4 regulates cristae remodeling in diabetic kidney disease. Nat Commun., 2024, 15(1): 1965

[78] Han F, Wu S, Dong Y, et al. . Aberrant expression of NEDD4L disrupts mitochondrial homeostasis by downregulating CaMKKβ in diabetic kidney disease. J Transl Med., 2024, 22(1): 465

[79] Kawano I, Bazila B, Ježek P, et al. . Mitochondrial dynamics and cristae shape changes during metabolic reprogramming. Antioxid Redox Signal., 2023, 39(10–12): 684-707

[80] Liu Q, Yan X, Yuan Y, et al. . HTRA2/OMI-mediated mitochondrial quality control alters macrophage polarization affecting systemic chronic inflammation. Int J Mol Sci., 2024, 25(3): 1577

[81] Wang Y, Guo Y, Xu Y, et al. . HIIT ameliorates inflammation and lipid metabolism by regulating macrophage polarization and mitochondrial dynamics in the liver of type 2 diabetes mellitus mice. Metabolites., 2022, 13(1): 14

[82] Ye S, Zhang M, Zheng X, et al. . YAP1 preserves tubular mitochondrial quality control to mitigate diabetic kidney disease. Redox Biol., 2024, 78 103435

[83] Xu YR, Lei CQ. TAK1-TABs complex: a central signalosome in inflammatory responses. Front Immunol., 2020, 11 608976

[84] Zeng H, Qi X, Xu X, et al. . TAB1 regulates glycolysis and activation of macrophages in diabetic nephropathy. Inflamm Res., 2020, 69(12): 1215-1234

[85] Fu J, Zang Y, Zhou Y, et al. . A novel triptolide derivative ZT01 exerts anti-inflammatory effects by targeting TAK1 to prevent macrophage polarization into pro-inflammatory phenotype. Biomedecine Pharmacother., 2020, 126 110084

[86] Chen Y, Jing J, Qingmin LI, et al. . Exploring the mechanism of Shenhua tablet alleviating renal injury by regulating macrophage glycolysis hypoxia-inducible factor-1α/pyruvate kinase M2 signaling pathway in diabetic kidney disease mice. Chung I Tsa Chih Ying Wen Pan., 2025, 45(3): 528-537

[87] Zhu XX, Zheng GL, Lu QB, et al. . Cichoric acid ameliorates sepsis-induced acute kidney injury by inhibiting M1 macrophage polarization. Eur J Pharmacol., 2024, 976 176696

[88] Li R, Shi C, Wei C, et al. . Fufang Shenhua tablet, astragali radix and its active component astragaloside IV: Research progress on anti-inflammatory and immunomodulatory mechanisms in the kidney. Front Pharmacol., 2023, 14: 1131635

[89] Peng K, Deng N, Meng Y, et al. . Alpha-momorcharin inhibits proinflammatory cytokine expression by M1 macrophages but not anti-inflammatory cytokine expression by M2 macrophages. J Inflamm Res., 2022, 15: 4853-4872

[90] Bahiraii S, Brenner M, Yan F, et al. . Sulforaphane diminishes moonlighting of pyruvate kinase M2 and interleukin 1β expression in M1 (LPS) macrophages. Front Immunol., 2022, 13 935692

[91] Ding H, Wang JJ, Zhang XY, et al. . Lycium barbarum polysaccharide antagonizes LPS-induced inflammation by altering the glycolysis and differentiation of macrophages by triggering the degradation of PKM2. Biol Pharm Bull., 2021, 44(3): 379-388

[92] Endale M, Park SC, Kim S, et al. . Quercetin disrupts tyrosine-phosphorylated phosphatidylinositol 3-kinase and myeloid differentiation factor-88 association, and inhibits MAPK/AP-1 and IKK/NF-κB-induced inflammatory mediators production in RAW 264.7 cells. Immunobiology, 2013, 218(12): 1452-1467

[93] Muffova B, Kauerova S, Paukner K, et al. . Anti-inflammatory effect of fluvastatin on polarized macrophages and its dependence on the mevalonate pathway. Sci Rep., 2025, 15(1): 19237

[94] Chen F, Wang N, Liao J, et al. . Esculetin rebalances M1/M2 macrophage polarization to treat sepsis-induced acute lung injury through regulating metabolic reprogramming. J Cell Mol Med., 2024, 28(21): e70178

[95] Tian W, Qiu H, He Y, et al. . Qinghao-Biejia Herb Pair attenuates SLE atherosclerosis by regulating macrophage polarization via ABCA1/G1-mediated cholesterol efflux. J Ethnopharmacol., 2024, 334 118545

[96] Lei XT, Pu DL, Shan G, et al. . Atorvastatin ameliorated myocardial fibrosis by inhibiting oxidative stress and modulating macrophage polarization in diabetic cardiomyopathy. World J Diabetes., 2024, 15(6): 1070-1073

[97] Dagar N, Habshi T, Shelke V, et al. . Renoprotective effect of esculetin against ischemic acute kidney injury-diabetic comorbidity. Free Radic Res., 2024, 58(2): 69-87

[98] Yang S, Ma C, Wu H, et al. . Tectorigenin attenuates diabetic nephropathy by improving vascular endothelium dysfunction through activating AdipoR1/2 pathway. Pharmacol Res., 2020, 153 104678

[99] Liu X, Wang T, Xiang R, et al. . Anti-inflammatory effects of 1, 7-dihydroxy-3, 4-dimethoxyxanthone through inhibition of M1-phenotype macrophages via arginine/mitochondrial axis. Immunol Res., 2024, 72(6): 1404-1416

[100] Ma S, He H, Ren X, et al. . Luteolin ameliorates periodontitis by modulating mitochondrial dynamics and macrophage polarization via the JAK2/STAT3 pathway. Int Immunopharmacol., 2025, 144 113612

[101] He XX, Huang YJ, Hu CL, et al. . Songorine modulates macrophage polarization and metabolic reprogramming to alleviate inflammation in osteoarthritis. Front Immunol., 2024, 15: 1344949

[102] Cao Y, Xiong J, Guan X, et al. . Paeoniflorin suppresses kidney inflammation by regulating macrophage polarization via KLF4-mediated mitophagy. Phytomedicine., 2023, 116 154901

[103] Zhong WJ, Zhang J, Duan JX, et al. . TREM-1 triggers necroptosis of macrophages through mTOR-dependent mitochondrial fission during acute lung injury. J Transl Med., 2023, 21(1): 179

[104] Zhou LY, Yao M, Tian ZR, et al. . Muscone suppresses inflammatory responses and neuronal damage in a rat model of cervical spondylotic myelopathy by regulating Drp1-dependent mitochondrial fission. J Neurochem., 2020, 155(2): 154-176

[105] Swaroop V, Ozkan E, Herrmann L, et al. . mTORC1 signaling and diabetic kidney disease. Diabetol Int., 2024, 15(4): 707-718

[106] Kdigo 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022 102(5S):S1–127.

[107] Rykova EY, Klimontov VV, Shmakova E, et al. . Anti-inflammatory effects of SGLT2 inhibitors: focus on macrophages. Int J Mol Sci., 2025, 26(4): 1670

[108] Moratal C, Laurain A, Naïmi M, et al. . Regulation of monocytes/macrophages by the renin-angiotensin system in diabetic nephropathy: state of the art and results of a pilot study. Int J Mol Sci., 2021, 22(11): 6009

[109] Haliga RE, Cojocaru E, Sîrbu O, et al. . Immunomodulatory effects of RAAS inhibitors: beyond hypertension and heart failure. Biomedicines., 2025, 13(7): 1779

[110] Sourris KC, Ding Y, Maxwell SS, et al. . Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic kidney disease through dampening the receptor for advanced glycation end products-induced inflammation. Kidney Int., 2024, 105(1): 132-149

[111] Zhang RM, Oh J, Wice BM, et al. . Acute hyperglycemia induces podocyte apoptosis by monocyte TNF-α release, a process attenuated by vitamin D and GLP-1 receptor agonists. J Steroid Biochem Mol Biol., 2025, 247 106676

[112] Sun Z, Zhang F, Gao Z, et al. . Liraglutide alleviates ferroptosis in renal ischemia reperfusion injury via inhibiting macrophage extracellular trap formation. Int Immunopharmacol., 2024, 142(Pt B): 113258

[113] Liu X, Zhang C, Fu Y, et al. . Inflammation, apoptosis, and fibrosis in diabetic nephropathy: molecular crosstalk in proximal tubular epithelial cells and therapeutic implications. Curr Issues Mol Biol., 2025, 47(11): 885

[114] Li ZH, Sun ZJ, Tang SCW, et al. . Finerenone alleviates over-activation of complement C5a–C5aR1 axis of macrophages by regulating G protein subunit alpha i2 to improve diabetic nephropathy. Cells., 2025, 14(5): 337

Funding

National Natural Science Foundation of China(31872746)

RIGHTS & PERMISSIONS

The Author(s)